Advertisement

Topics

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

2014-08-27 03:15:50 | BioPortfolio

Summary

To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Conditions

Glucose Lowering

Intervention

AZD1656

Location

Research Site
Orlando
Florida
United States

Status

Not yet recruiting

Source

AstraZeneca

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:15:50-0400

Clinical Trials [1087 Associated Clinical Trials listed on BioPortfolio]

A Study to Evaluate Safety and Tolerability After Oral Dosing of AZD1656 in Healthy Volunteers

The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects

To Evaluate the Bioavailability of a Tablet of AZD1656

To evaluate the bioavailability of a tablet of AZD1656.

Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes

The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.

Study To Assess the Pharmacokinetics of AZD1656 During Coadministration With Simvastatin

To assess the pharmacokinetics of AZD1656 during coadministration with Simvastatin.

PubMed Articles [3243 Associated PubMed Articles listed on BioPortfolio]

Mechanisms of metformin action: in and out of the gut.

One hundred years have passed since guanidine, a precursor compound of biguanides and thus of metformin, was found to have a glucose-lowering effect in live animals . In this historical study, C. K. W...

A systematic review of measures estimates adherence and persistence to multiple medications.

We reviewed measures used to estimate adherence and persistence to multiple cardiometabolic medications from prescription data, particularly for blood pressure-lowering, lipid-lowering, and/or glucose...

Rifampicin alters metformin plasma exposure but not blood glucose levels in diabetic tuberculosis patients.

The pharmacokinetic and clinical implications of combining metformin with rifampicin are relevant to increasing numbers of diabetic tuberculosis (TB) patients across the world and are yet unclear. We ...

Durability of Glucose-Lowering Effect of the First Administration of Dulaglutide: A Retrospective, Single-Center, Single-Arm Study.

Dulaglutide (Dula) is a once-weekly glucagon-like peptide-1 receptor agonist that efficiently reduces the level of glycated hemoglobin (HbA1c) in patients with type 2 diabetes (T2D). However, the dura...

Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.

The authors conducted a systematic review and network meta-analysis of placebo-controlled, randomized clinical trials in the post-Food and Drug Administration (FDA) guidance era to formally compare th...

Medical and Biotech [MESH] Definitions

Maintenance of a constant blood glucose level by perfusion or infusion with glucose or insulin. It is used for the study of metabolic rates (e.g., in glucose, lipid, amino acid metabolism) at constant glucose concentration.

A glucose transport facilitator that is expressed primarily in PANCREATIC BETA CELLS; LIVER; and KIDNEYS. It may function as a GLUCOSE sensor to regulate INSULIN release and glucose HOMEOSTASIS.

A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

An enzyme that catalyzes the conversion of D-glucose 6-phosphate and water to D-glucose and orthophosphate. EC 3.1.3.9.

A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg).

More From BioPortfolio on "To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...


Searches Linking to this Trial